Berg DD, Wiviott SD, Scirica BM, et al. – Researchers developed and validated a practical clinical risk score for hospitalization for heart failure (HHF) in patients with type 2 diabetes mellitus (T2DM). In addition, they assessed this score for its utility in the identification of high-risk patients with T2DM who have the greatest reduction in risk for HHF with a sodium-glucose cotransporter-2 inhibitor. They created a clinical risk score for HHF in 8,212 patients with T2DM in the placebo arm of Saxagliptin Assessment of Vascular Outcomes Recorded in Patients With Diabetes Mellitus–Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53). Independent risk predictors of HHF included prior heart failure, history of atrial fibrillation, coronary artery disease, estimated glomerular filtration rate, and urine albumin-to-creatinine ratio. A simple integer-based score (0–7 points) developed using these predictors led to the discovery of a > 20-fold gradient of HHF risk among patients with T2DM. These patients at greater risk may derive greater absolute benefit from sodium-glucose cotransporter-2 inhibition.